Brexafemme approved for recurrent yeast infection

Brexafemme Approved For Recurrent Yeast Infections


The Food and Drug Administration (FDA) has approved Brexafemme for a second indication for reduction in incidence of recurrent vulvovaginal candidiasis, Scynexis announced Thursday

“Brexafemme was already the only non-azole oral therapy available for VVC and is now the only therapy FDA-approved for both VVC and RVVC,” said Marco Taglietti, M.D., President and Chief Executive Officer of Scynexis.

The FDA accepted the application for the second use last summer and the approval followed positive results from a trial that showed 65.4% of patients had no recurrence of yeast infection vs. 53.1% in a placebo group after a three-month follow-up period.

The most common adverse responses were headache or gastrointestinal and were mostly mild, the company reported.

With the FDA approval, the tablets can now be prescribed for patients with both VVC and RVCC.

The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

Let Us Know What You Think

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


More Perspectives